The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
Abstract
Purpose Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects. Our aim was to perform image-based absorbed dose calculation for the new PSMA ligand (177)Lu-DKFZ-PSMA-617 in support of its use for the treatment of metastatic prostate cancer.Methods Whole-body planar images and SPECT/CT images of the abdomen were acquired in five patients (mean age 68 years) for during two treatment cycles at approximately 1, 24, 48 and 72 h after administration of 3.6 GBq (range 3.4 to 3.9 GBq) (177)Lu-DKFZ-PSMA-617. Quantitative 3D SPECT OSEM reconstruction was performed with corrections for photon scatter, photon attenuation and detector blurring. A camera-specific calibration factor derived from phantom measurements was used for quantitation. Absorbed doses were calculated for various organs from the images using a combination of linear approximation, exponential fit, and target-specific S values, in accordance with the MIRD scheme. Absorbed doses to bone marrow were estimated from planar and SPECT images and with consideration of the blood sampling method according to the EANM guidelines.Results The average (± SD) absorbed doses per cycle were 2.2 ± 0.6 Gy for the kidneys (0.6 Gy/GBq), 5.1 ± 1.8 Gy for the salivary glands (1.4 Gy/GBq), 0.4 ± 0.2 Gy for the liver (0.1 Gy/GBq), 0.4 ± 0.1 Gy for the spleen (0.1 Gy/GBq), and 44 ± 19 mGy for the bone marrow (0.012 Gy/GBq). The organ absorbed doses did not differ significantly between cycles. The critical absorbed dose reported for the kidneys (23 Gy) was not reached in any patient. At 24 h there was increased uptake in the colon with 50 - 70 % overlap to the kidneys on planar images. Absorbed doses for tumour lesions ranged between 1.2 and 47.5 Gy (13.1 Gy/GBq) per cycle.Conclusion The salivary glands and kidneys showed high, but not critical, absorbed doses after RLT with (177)Lu-DKFZ-PSMA-617. We suggest that (177)Lu-DKFZ-PSMA-617 is suitable for radiotherapy, offering tumour-to-kidney ratios comparable to those with RLT agents currently available for the treatment of neuroendocrine tumours. Our dosimetry results suggest that (177)Lu-DKFZ-PSMA-617 treatment with higher activities and more cycles is possible without the risk of damaging the kidneys.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Delker et al. estimated a mean of 1.4 Gy/GBq to the salivary glands from 177 Lu-PSMA-617 therapies ( 77 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [77]
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
Accelerated image reconstruction using ordered subsets of projection data
Hudson, H. M., & Larkin, R. S. (1994) · IEEE Transactions on Medical Imaging · doi:10.1109/42.363108 · Cited by 3,713
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
(1997) · PubMed · Cited by 1,541
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L. R., van Eijck, C. H. J., van Essen, M., Kooij, P. P. M., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,454
Bayesian reconstructions from emission tomography data using a modified EM algorithm
Green, P. J. (1990) · IEEE Transactions on Medical Imaging · doi:10.1109/42.52985 · Cited by 1,242
Afshar‐Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H., Hadaschik, B. A., Holland‐Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 919
Self-citationTumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 883
Zaknun, J. J., Bodei, L., Mueller‐Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O'Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 837
Flagged first, then by citations
Research works printed but not linked: 1
- Siegel J, Wessels B, Watson E, Stabin M, Vriesendorp H, Bradley E, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharm. 1990;3:213–34.
Cited by
Sorted by citations
Items 201–300 of 318
Alkahtani, T. O. (2025) · BMC Medical Imaging · doi:10.1186/s12880-025-01571-x · Cited by 7
Organs dosimetry in targeted radionuclide therapy
Alnaaimi, M., Sulieman, A., Alkhorayef, M. A., Salah, H., Alduaij, M., Algaily, M., Alomair, O. I., Alashban, Y. I., Almohammad, H. I., Bradley, D. A., et al. (2021) · Radiation Physics and Chemistry · doi:10.1016/j.radphyschem.2021.109668 · Cited by 7
A step toward simplified dosimetry of radiopharmaceutical therapy via SPECT frame duration reduction
Yazdani, E., Asadi, M., Geramifar, P., Ziarati, N. K., Vosoughi, H., Kazemi-Jahromi, M., & Sadeghi, M. (2024) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2024.111378 · Cited by 7
JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging
Nedelcovych, M. T., Dash, R. P., Wu, Y., Choi, E. Y., Lapidus, R. S., Majer, P., Jančařík, A., Abou, D. S., Penet, M., Nikolopoulou, A., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07044-7 · Cited by 7
Self-citationHaberkorn, U., Kratochwil, C., Mamlins, E., Mori, Y., & Giesel, F. L. (2020) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-42618-7_29 · Cited by 7
Self-citationA Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?
Gupta, M., Karthikeyan, G., Choudhury, P. S., Koyyala, V. P. B., Sharma, M. R., Jain, P., Talwar, V., Singh, A. D., & Rawal, S. K. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1811301 · Cited by 7
Pre-Therapeutic Dosimetry Employing Scandium-44 for Radiolabeling PSMA-617
Eppard, E. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79157 · Cited by 7
Prostate cancer Monte Carlo dose model with 177Lutetium and 125Iodine treatments
Juste, B., Miró, R., Morató, S., Verdú, G., & Peris, S. (2020) · Radiation Physics and Chemistry · doi:10.1016/j.radphyschem.2020.108908 · Cited by 7
Ceci, F., Castellucci, P., Polverari, G., & Iagaru, A. H. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000794 · Cited by 8
In vitro and in vivo response of PSMA-617 radiolabeled with CA and NCA lutetium-177
Boas, C. A. W. V., Silva, J. D. J., Dias, L. A. P., Freire, M. R. B., Balieiro, L. M., dos Santos, C. S. F., Vivaldini, B. F., Benedetto, R., Vieira, D. P., Passos, P. D. Q. S., et al. (2021) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2021.110064 · Cited by 7
Fitzpatrick, K. J., Mikell, J. K., Roseland, M. E., Niedbala, J., Suresh, K., Peterson, A., Viglianti, B. L., Wong, K. K., Frey, K. A., & Dewaraja, Y. K. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.06.3869 · Cited by 6
Rumiantcev, M., Resch, S., Liubchenko, G., Sheikh, G. T., Zacherl, M. J., Werner, R. A., Ziegler, S. I., Böning, G., & Delker, A. (2025) · Cancers · doi:10.3390/cancers17142313 · Cited by 6
Self-citationLu-177 Prostate Specific Membrane Antigen Therapy of Metastatic Castration Resistant Prostate Cancer
Demirci, E., & Kabasakal, L. (2018) · Nuclear Medicine Seminars · doi:10.4274/nts.2018.028 · Cited by 6
Physics-Guided Deep Scatter Estimation by Weak Supervision for Quantitative SPECT
Kim, H., Li, Z., Son, J., Fessler, J. A., Dewaraja, Y. K., & Chun, S. Y. (2023) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2023.3270868 · Cited by 6
Dosimetry for Radiopharmaceutical Therapy
International Atomic Energy Agency (2024) · International Atomic Energy Agency eBooks · doi:10.61092/iaea.xlzb-6h67 · Cited by 7
Maroufpour, S., Aryana, K., Nasseri, S., Fazeli, Z., Arabi, H., & Momennezhad, M. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00691-7 · Cited by 6
Recent advances in nuclear medicine in endocrine oncology
Luster, M., Pfestroff, A., & Verburg, F. A. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000338 · Cited by 6
Kunert, J.-P., Fischer, S., Wurzer, A. J., & Wester, H. (2022) · Pharmaceuticals · doi:10.3390/ph15091161 · Cited by 6
Ong, W. M., Zargar‐Shoshtari, K., Siva, S., & Zargar, H. S. (2018) · Minerva Urologica e Nefrologica · doi:10.23736/s0393-2249.18.03152-1 · Cited by 6
Meléndez‐Alafort, L., Ferro‐Flores, G., Santos‐Cuevas, C., Ocampo‐García, B., Turato, S., Fracasso, G., Bolzati, C., Rosato, A., & Nardo, L. D. (2021) · Medical Physics · doi:10.1002/mp.14936 · Cited by 6
JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted RadiotherapyPreprint
Nedelcovych, M. T., Dash, R. P., Wu, Y., Choi, E. Y., Lapidus, R. S., Majer, P., Abou, D. S., Penet, M., Nikolopoulou, A., Amor-Coarasa, A., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/457085 · Cited by 6
Self-citationDuong, T. T., Sarno, D. D., Fakir, H., Bauman, G. S., Martinov, M., Thomson, R. M., & Lee, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1600821 · Cited by 5
Peterson, A., Wilderman, S. J., Blakkisrud, J., Wong, K. K., Frey, K. A., & Dewaraja, Y. K. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00816-6 · Cited by 5
Nuklearmedizinische Diagnostik und Therapie des Prostatakarzinoms
Grunert, M., Eberhardt, N., Prasad, V., & Beer, A. J. (2021) · Journal für Urologie und Urogynäkologie/Österreich · doi:10.1007/s41972-021-00134-w · Cited by 5
Towards personalized patient 3D Monte Carlo dosimetry for Lu-177-psma prostate treatments
Ribes, V., Oliver, S., Juste, B., Miró, R., & Verdú, G. (2024) · Radiation Physics and Chemistry · doi:10.1016/j.radphyschem.2024.111890 · Cited by 5
Radiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Danieli, R., Chiesa, C., & ZANZONICO, P. B. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_6 · Cited by 5
Bedeutung und Nutzen von PSMA-Liganden beim Prostatakarzinom
Gasch, C., Körber, S. A., Kremer, C., Eiber, M., Kratochwil, C., Haberkorn, U., Hohenfellner, M., Hadaschik, B. A., & Giesel, F. (2017) · Aktuelle Urologie · doi:10.1055/s-0043-100269 · Cited by 5
Self-citationParticle filter de-noising of voxel-specific time-activity-curves in personalized 177 Lu therapy
Götz, T. I., Lang, E. W., Schmidkonz, C., Maier, A., Kuwert, T., & Ritt, P. (2019) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2019.10.005 · Cited by 5
Krishnan, M. A., Pandit, A., Sharma, R., & Chelvam, V. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1936642 · Cited by 5
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice
Klose, J. M., Wosniack, J., Iking, J., Staniszewska, M., Zarrad, F., Trajkovic‐Arsic, M., Herrmann, K., Costa, P. F., Lückerath, K., & Fendler, W. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263453 · Cited by 5
Self-citationErmert, J., Benešová, M., Hugenberg, V., Gupta, V., Spahn, I., Pietzsch, H., Liolios, C. C., & Kopka, K. (2020) · Springer eBooks · doi:10.1007/978-3-030-39457-8_2 · Cited by 5
Self-citationGötz, T., Lang, E. W., Prante, O., Cordes, M., Kuwert, T., Ritt, P., Ludwig, B., & Schmidkonz, C. (2020) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-1204-9932 · Cited by 5
Aryana, K., Moghadam, S. Z., Salek, R., & Divband, G. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001986 · Cited by 5
Verburg, F. A., & Luster, M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3767-4 · Cited by 5
Zhang-Yin, J. T. (2024) · Biomedicines · doi:10.3390/biomedicines12071512 · Cited by 4
Quantitative Bildgebung für die Dosimetrie mit SPECT/CT
Tran‐Gia, J., Laßmann, M., Kuwert, T., & Ritt, P. (2018) · Der Nuklearmediziner · doi:10.1055/s-0043-121899 · Cited by 4
Theranostics in Metastatic Castrate Resistant Prostate Cancer
Vorster, M., & Sathekge, M. M. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.prostatecancer.theranostics.2021 · Cited by 4
Radionuclides in oncology clinical practice – review of the literature
Pais, H. L., Alho, I., Vendrell, I., Mansinho, A., & Costa, L. (2017) · Dalton Transactions · doi:10.1039/c7dt01929g · Cited by 4
Chopra, S., Oinam, A. S., Singh, G., Kaur, K., Mittal, B., & Shukla, J. (2025) · Physics in Medicine and Biology · doi:10.1088/1361-6560/adfc22 · Cited by 3
Zhang, J., Lin, Z., Zhang, X., Lin, R., Cui, M., Zang, J., Miao, W., & Yao, S. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.811972 · Cited by 4
Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol
Sezgın, C., Uygur, E., Parlak, Y., Karatay, K. B., Barutça, S., Dirican, A., Sözen, T., Aslan, G., Harmanşah, Ç., Toklu, T., et al. (2025) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-025-10352-3 · Cited by 2
Liubchenko, G., Böning, G., Rumiantcev, M., Zounek, A. J., Zacherl, M. J., Sheikh, G. T., Resch, S., Werner, R. A., Ziegler, S. I., & Delker, A. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00800-0 · Cited by 2
Self-citationReview of radiopharmaceutical therapy in prostate cancer
Miller, S. R., Dewaraja, Y. K., Rowe, S. P., Reichert, Z. R., & Viglianti, B. L. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.111030 · Cited by 2
Al‐Ibraheem, A., Istatieh, F., Abdlkadir, A. S., Abufara, A., Sharaf, B., Abu-Hijlih, R. A., Al-Hajaj, N., & Salah, S. H. (2024) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-2311-5679 · Cited by 2
Yilidir, G., & Demır, M. (2024) · Journal of Medical Physics · doi:10.4103/jmp.jmp_12_24 · Cited by 2
Procedure Guidelines for Lu-177 PSMA Radyoligand Treatment
Sivrikoz, İ. A., Uçmak, G., Kaya, G. Ç., Demirci, E., Selçuk, N. A., Türkmen, C., Elboğa, U., & Kabasakal, L. (2020) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2020.0031 · Cited by 2
Prostate cancer imaging and therapy
Zanoni, L., Nanni, C., Fanti, S., Béhé, M. P., Römer, W., Tempesta, D., Gilmore, D., Testanera, G., Pepe, G., Tsang, Y. M., et al. (2018) · doi:10.52717/gpjl7081 · Cited by 2
The Synergy Between Ionizing Radiation and Immunotherapy in the Treatment of Prostate Cancer
Sathianathen, N. J., Krishna, S. R., Konety, B. R., & Griffith, T. S. (2017) · Immunotherapy · doi:10.2217/imt-2017-0051 · Cited by 2
Dosimetrie bei der Radionuklidtherapie mit Lu-177
Gosewisch, A., Ilhan, H., Vomacka, L., & Böning, G. (2018) · Der Nuklearmediziner · doi:10.1055/s-0043-122171 · Cited by 2
Self-citationVarshney, R. (2020) · Novel Approaches in Cancer Study · doi:10.31031/nacs.2020.05.000611 · Cited by 2
Yadav, M. P., Ballal, S., & Bal, C. (2017) · Journal of Radiology and Oncology · doi:10.29328/journal.jro.1001012 · Cited by 1
Gupta, M., Karthikeyan, G., Choudhury, P. S., Sharma, A., & Rawal, S. K. (2020) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.28.156 · Cited by 1
Lu-177-PSMA Treatment in Prostate Cancer
Kairemo, K. (2025) · Springer eBooks · doi:10.1007/978-3-031-90337-3_14 · Cited by 1
Cao, J., Sun, Z., Zhou, Z., Huang, Y., Peng, D., Jiang, X., & Chen, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-05344-y · Cited by 1
Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Prostate Cancer Models
Ferreira, C. A., Potluri, H. K., Tantawy, A. A., Massey, C. F., Grudzinski, J. J., Carston, A. M., Clemons, N. C., Idrissou, M. B., Thickens, A. S., Rosenkrans, Z. T., et al. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.09.072 · Cited by 1
Happel, C., Völler, L., Bockisch, B., Groener, D., Leonhäuser, B., Grünwald, F., & Sabet, A. (2025) · Molecular Imaging and Biology · doi:10.1007/s11307-025-01998-2 · Cited by 1
Alshehri, A. H. D., & Živković, M. P. (2026) · Radiation Physics and Chemistry · doi:10.1016/j.radphyschem.2026.113748 · Cited by 1
Accuracy of quantitative 177 Lu SPECT/CT imaging: A systematic review
van Oorschodt, J. C. J., Eslick, G. D., Ugander, M., van Pul, C., & Eslick, E. M. (2026) · Medical Physics · doi:10.1002/mp.70554 · Cited by 1
Novel imaging in advanced prostate cancer
Goldberg, H., & Hamilton, R. J. (2017) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000275 · Cited by 1
Aras, Ö., Harmsen, S., Ting, R., & Sayman, H. B. (2021) · Acta Radiologica Open · doi:10.1177/20584601211022509 · Cited by 1
Morgan, K. A., & Donnelly, P. S. (2021) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2021.05.002 · Cited by 1
Radiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Danieli, R., Chiesa, C., & ZANZONICO, P. B. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_6-2 · Cited by 1
Feasibility of 177Lu activity quantification using a small portable CZT-based gamma-camera
Roth, D., Larsson, E., Strand, J., Ljungberg, M. H., & Gleisner, K. S. (2024) · EJNMMI Physics · doi:10.1186/s40658-023-00602-2 · Cited by 1
Gabiña, P. M., Vela, N. C., Rosales, L. I., Martí-Climent, J. M., Gómez, L. C. M., Fuentes, T., Fuentes, C. M., Uruen, A. M., & Sanz, R. B. (2024) · Revista de Física Médica · doi:10.37004/sefm/2024.25.2.003 · Cited by 1
Radiological Technology for Targeted Radionuclide Therapy
Hanaoka, K., Miyaji, N., Yoneyama, H., Ogawa, M., Maeda, T., Sakaguchi, K., Iimori, T., & Tsushima, H. (2020) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.2020_jsrt_76.12.1237 · Cited by 1
First individualized patient dosimetry in radionuclide therapy with 177Lu-PSMA-CC34 in Indonesia
Hidayati, N. R., Mailana, W., Dewi, A. R., Rosilawaty, E., Shintawati, R., & Kartamihardja, A. H. S. (2021) · AIP conference proceedings · doi:10.1063/5.0066286 · Cited by 1
Moving Forward: Expected Opportunities for the Development of New Therapeutic Agents
Cohen, P. F., de Godoy, T. R. M., & Kairemo, K. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_21 · Cited by 1
Thoughts on “Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?”
Privé, B. M., Peters, S. M. B., Uijen, M. J. M., Janssen, M. J. R., van Gemert, W. A. M., Kreissl, M. C., Ezzidin, S., Konijnenberg, M. W., & Nagarajah, J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.263802 · Cited by 1
PSMA-Based Therapy of Metastasized Castrate-Resistant Prostate Cancer
Schwarzenböck, S. M., Kurth, J., Nitsch, S., & Krause, B. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-63067-0_34
Turpin, L., Calzada-Nocaudie, M., Zhang-Yin, J. T., Rusu, T., Bruzek, A. D., Aveline, C., Sgard, B., Nataf, V., Cussenot, O., Montravers, F., et al. (2019) · Médecine Nucléaire · doi:10.1016/j.mednuc.2019.03.002
Radioligand Therapy in Prostate Cancer Using PSMA Ligands
Seifert, R., & Rahbar, K. (2020) · Springer eBooks · doi:10.1007/978-3-030-39457-8_40
Kreppel, B., Gaertner, F. C., & Essler, M. (2020) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-1152-2279
Marin, S. P. (2020) · cIRcle (University of British Columbia) · doi:10.14288/1.0394162
Therapie mit 177Lu-PSMA: Stand der Dinge
Essler, M. (2020) · Der Nuklearmediziner · doi:10.1055/a-1109-5278
Neue Wege der interdisziplinären Kooperation: ASV bei urologischen Tumoren
Roigas, J., Hölzer, W., & Zillmann, R. (2020) · Der Nuklearmediziner · doi:10.1055/a-1107-3965
Spicing up prostate cancer theranostics
van Kalmthout, L. W. M. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/334
Boas, C. A. W. V. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.85.2020.tde-23122020-094716
Dosimetry For 177Lu-PSMA Therapies
Alawi, S. M. (2021) · UEF eRepo (University of Eastern Finland)
Neue Wege der interdisziplinären Kooperation: ASV bei urologischen Tumoren
Roigas, J., Hölzer, W., & Zillmann, R. (2021) · TumorDiagnostik & Therapie · doi:10.1055/a-1502-8817
Diagnostic role of gastrin-releasing peptide receptors in oncology
Korol, P. O., & Щербіна, О. В. (2021) · Radiation Diagnostics Radiation Therapy · doi:10.37336/2707-0700-2021-1-3
Side effects of therapy with radiolabelled prostate specific membrane antigen (PSMA)
Emmett, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00150-2
(2018) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2018-43s505
Brosch-Lenz, J., Uribe, C., Gosewisch, A., Kaiser, L., Todica, A. S., Ilhan, H., Gildehaus, F. J., Bartenstein, P., Rahmim, A., Celler, A. M., et al. (2020) · doi:10.21203/rs.3.rs-50788/v1
Self-citationRadiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Danieli, R., Chiesa, C., & ZANZONICO, P. B. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_6-3
Radionuclide Therapy in Prostate Cancer
Acar, E., Bekiş, R., & Polack, B. (2022) · Springer eBooks · doi:10.1007/978-3-030-97220-2_15
Said, M. A., Razak, H. R. A., & Musarudin, M. (2022) · Journal of Medical Physics · doi:10.4103/jmp.jmp_82_21
Privé, B. M., Peters, S. M. B., Muselaers, S., van Oort, I. M., Janssen, M. J. R., Sedelaar, J. P. M., Konijnenberg, M., Zámecnik, P., Uijen, M. J. M., Schilham, M. G. M., et al. (2023) · doi:10.1158/1078-0432.c.6530696
Therapeutic management of hormone-dependent cancers in transgender patients
Mihalopoulos, M., Crowley, F., Lundon, D., & Kyprianou, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98377-8.00002-6
PSMA in Diagnostik und Therapie
Fink, C. A., Mamlins, E., Cardinale, J., Körber, S. A., & Giesel, F. L. (2024) · Springer eBooks · doi:10.1007/978-3-662-67192-4_11
Kovan, B. (2024) · Istanbul Medical Journal · doi:10.4274/imj.galenos.2024.33410
Pattanawong, O., Charoenphun, P., Chamroonrat, W., Thongpraparn, T., Poon-Iad, N., Khiewvan, B., & Chuamsaamarkkee, K. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14187
Dosimetry Methods for Radiopharmaceuticals
Rana, N., Chopra, S., & Kaur, K. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00159
Kupitz, D., Wissel, H., Wuestemann, J., Bluemel, S., Pech, M., Amthauer, H., Kreissl, M. C., & Großer, O. S. (2021) · Figshare · doi:10.6084/m9.figshare.15086222
Grob, D., Privé, B. M., Muselaers, S., Mehra, N., Nagarajah, J., Konijnenberg, M. W., & Peters, S. M. B. (2024) · Figshare · doi:10.6084/m9.figshare.26701663
Meyer, C., Prasad, V. S. S. D., Stuparu, A. D., Kletting, P., Glatting, G., Miksch, J., Solbach, C., Lueckerath, K., Nyiranshuti, L., Zhu, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21259040
Kupitz, D., Wissel, H., Wuestemann, J., Bluemel, S., Pech, M., Amthauer, H., Kreissl, M. C., & Großer, O. S. (2021) · Figshare · doi:10.6084/m9.figshare.15086228
Roll, W., Müther, M., Böning, G., Delker, A., Warneke, N., Gildehaus, F.-J., Schäfers, M., Stummer, W., Zeidler, R., Reulen, H.-J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24089008
Self-citation
Metadata
- Authors
- Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., Bartenstein, P., & Böning, G.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University Hospital Heidelberg (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Böning, Guido
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2015-08-29
- Volume
- 43
- Issue
- 1
- Pages
- 42-51
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W1140456871
- Cited by
- 322
- References
- 42
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 31 · 2021: 51 · 2020: 41 · 2019: 33 · 2018: 32 · 2017: 27 · 2016: 26 · 2015: 1
- FWCI
- 23.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutschen Konsortium für Translationale Krebsforschung
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
- Keywords
- radioligand therapy, dosimetry, absorbed dose, metastatic prostate cancer, PSMA ligands, SPECT/CT, kidney dose, salivary gland dose, bone marrow dose, critical organ dose, tumor dose, EANM guidelines
- MeSH terms
- Aged, Aged, 80 and over, Antigens, Surface, Humans, Male, Middle Aged, Neoplasm Metastasis, Organometallic Compounds, Peptides, Radiometry, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
